VBL Therapeutics

VBL Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for difficult-to-treat malignant solid tumors and immune or inflammatory conditions. VBL's lead oncology candidate, ofranergene obadenovec (VB-111; 'ofra-vec'), is an investigational, first-in-class, targeted anti-cancer gene-based drug being developed for the treatment of multiple solid tumors. VB-111 is currently in a Phase 3 registration clinical trial (NCT03398655) for platinum-resistant ovarian cancer.